{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T04:07:15Z","timestamp":1792296435749,"version":"4.4.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Heat shock protein 90 (Hsp90) is a molecular chaperone that plays a critical role in stabilizing and regulating numerous client proteins involved in inflammation, immune activation, and skin barrier homeostasis. Emerging evidence suggests that Hsp90 contributes to the pathophysiology of atopic dermatitis (AD), a chronic inflammatory skin disorder characterized by immune dysregulation, epidermal barrier dysfunction, and microbial imbalance. Notably, elevated intracellular Hsp90 activity has been reported in peripheral blood leukocytes of AD patients, alongside increased extracellular Hsp90 and anti-Hsp90 IgE antibodies. Preclinical studies employing murine models of AD, including dinitrochlorobenzene (DNCB)- and calcipotriol (MC903)-induced dermatitis, have demonstrated that both topical and systemic inhibition of Hsp90 ameliorates disease severity. These improvements correlate with reduced epidermal hyperplasia, decreased expression of Th\/Th2 cytokines, attenuation of keratinocyte-derived alarmins, and suppression of inflammation. Additionally, Hsp90 inhibition limits the infiltration or activation of immune cells such as T cells, neutrophils, eosinophiles, and mast cells in the skin. Mechanistic investigations reveal that Hsp90 blockade downregulates key signaling pathways implicated in AD pathogenesis, notably NF-\u03baB and JAK-STAT. <jats:italic>In vitro<\/jats:italic> studies further corroborate that Hsp90 inhibition reduces proinflammatory responses in keratinocytes, CD4<jats:sup>+<\/jats:sup> T cells, and eosinophils. Beyond modulating skin inflammation, Hsp90 blockade partially restores gut microbiota dysbiosis and impairs <jats:italic>Staphylococcus aureus<\/jats:italic> biofilm formation, both relevant to AD pathogenesis. Although clinical data on Hsp90 inhibitors in AD are still lacking, early-phase trials in psoriasis and hidradenitis suppurativa suggest potential therapeutic benefit. Collectively, these findings underscore a multifaceted role for Hsp90 in AD and support its potential as a promising novel therapeutic target.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1658399","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T04:11:02Z","timestamp":1756354262000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Hsp90 as a pathophysiological factor and emerging therapeutic target in atopic dermatitis"],"prefix":"10.3389","volume":"16","author":[{"given":"Stefan","family":"Tukaj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18225","article-title":"Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options","volume":"36","author":"Bieber","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/all.16007","article-title":"Impact of climate change on atopic dermatitis: A review by the International Eczema Council","volume":"79","author":"Wang","year":"2024","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02519-4","article-title":"Atopic dermatitis","volume":"405","author":"Guttman-Yassky","year":"2025","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2023.04.052","article-title":"Phenotypic and endotypic determinants of atopic dermatitis severity from the atopic dermatitis research network (ADRN) registry","volume":"11","author":"Simpson","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.01.042","article-title":"Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis","volume":"145","author":"He","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2025.100377","article-title":"The role of skin dysbiosis and quorum sensing in atopic dermatitis","volume":"5","author":"Okamoto","year":"2025","journal-title":"JID Innov"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e70130","DOI":"10.1111\/pai.70130","article-title":"Environmental factors shaping atopic dermatitis: Lessons from longitudinal cohort studies","volume":"36","author":"Lee","year":"2025","journal-title":"Pediatr Allergy Immunol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/1744666X.2025.2452247","article-title":"Biologics and small molecules: the re-evolution in the treatment of atopic dermatitis in children and adolescents. Current state of the art and future perspectives","volume":"21","author":"D\u2019Auria","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03124-8","article-title":"Onset and long-term maintenance of optimal itch response in adult patients with moderate-to-severe atopic dermatitis treated with dupilumab: post hoc analysis from two phase 3 trials","volume":"42","author":"St\u00e4nder","year":"2025","journal-title":"Adv Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20880","article-title":"HSP90 inhibitor RGRN - 305 for oral treatment of plaque-type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study","volume":"186","author":"Bregnh\u00f8j","year":"2022","journal-title":"Br J Dermatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/biom12081153","article-title":"Heat shock protein 90 (Hsp90) and hsp70 as potential therapeutic targets in autoimmune skin diseases","volume":"12","author":"Tukaj","year":"2022","journal-title":"Biomolecules"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.20","article-title":"The HSP90 chaperone machinery","volume":"18","author":"Schopf","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1436973","article-title":"HSP90 multi-functionality in cancer","volume":"15","author":"Albakova","year":"2024","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.REV120.011833","article-title":"Post-translational modifications of Hsp90 and translating the chaperone code","volume":"295","author":"Backe","year":"2020","journal-title":"J Biol Chem"},{"key":"B16","doi-asserted-by":"publisher","first-page":"6899","DOI":"10.1038\/s41598-018-25329-4","article-title":"Dissecting structure-encoded determinants of allosteric cross-talk between post-translational modification sites in the hsp90 chaperones","volume":"8","author":"Stetz","year":"2018","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3892\/or.2022.8443","article-title":"HSP90 inhibitors and cancer: Prospects for use in targeted therapies (Review)","volume":"49","author":"Li","year":"2023","journal-title":"Oncol Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7601579","article-title":"Extracellular heat shock protein-90alpha: linking hypoxia to skin cell motility and wound healing","volume":"26","author":"Li","year":"2007","journal-title":"EMBO J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1131","article-title":"Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness","volume":"6","author":"Eustace","year":"2004","journal-title":"Nat Cell Biol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314609","article-title":"Heat-shock protein 90 inhibition in autoimmunity to type VII collagen: evidence that nonmalignant plasma cells are not therapeutic targets","volume":"117","author":"Kasperkiewicz","year":"2011","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.08.032","article-title":"Topically applied hsp90 blocker 17AAG inhibits autoantibody-mediated blister-inducing cutaneous inflammation","volume":"137","author":"Tukaj","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12680","article-title":"Heat shock protein 90 is required for ex vivo neutrophil-driven autoantibody-induced tissue damage in experimental epidermolysis bullosa acquisita","volume":"24","author":"Tukaj","year":"2015","journal-title":"Exp Dermatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"e70496","DOI":"10.1371\/journal.pone.0070496","article-title":"Aberrant expression and secretion of heat shock protein 90 in patients with bullous pemphigoid","volume":"8","author":"Tukaj","year":"2013","journal-title":"PloS One"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s12192-014-0513-8","article-title":"Hsp90 blockade modulates bullous pemphigoid IgG-induced IL - 8 production by keratinocytes","volume":"19","author":"Tukaj","year":"2014","journal-title":"Cell Stress Chaperones"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/exd.12476","article-title":"Immunomodulatory effects of heat shock protein 90 inhibition on humoral immune responses","volume":"23","author":"Tukaj","year":"2014","journal-title":"Exp Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12192-014-0505-8","article-title":"Evidence for a role of autoantibodies to heat shock protein 60, 70, and 90 in patients with dermatitis herpetiformis","volume":"19","author":"Kasperkiewicz","year":"2014","journal-title":"Cell Stress Chaperones"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s12192-021-01238-w","article-title":"Circulating heat shock protein 90 (Hsp90) and autoantibodies to Hsp90 are increased in patients with atopic dermatitis","volume":"26","author":"Sitko","year":"2021","journal-title":"Cell Stress Chaperones"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1327144","article-title":"Differences in the detection of circulating Hsp90 alpha between patients with atopic dermatitis and dermatitis herpetiformis","volume":"10","author":"Sitko","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s12192-023-01387-0","article-title":"Heat shock protein 90 (Hsp90) inhibitor STA - 9090 (Ganetespib) ameliorates inflammation in a mouse model of atopic dermatitis","volume":"28","author":"Sitko","year":"2023","journal-title":"Cell Stress Chaperones"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1289788","article-title":"Heat shock protein 90 inhibition attenuates inflammation in models of atopic dermatitis: a novel mechanism of action","volume":"14","author":"Ben Abdallah","year":"2024","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"21245","DOI":"10.1038\/s41598-025-05307-3","article-title":"Topical application of the HSP90 inhibitor 17-AAG reduces skin inflammation and partially restores microbial balance: implications for atopic dermatitis therapy","volume":"15","author":"Sitko","year":"2025","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2101023","article-title":"Heat shock protein 90\u2019s mechanistic role in contact hypersensitivity","volume":"208","author":"Kim","year":"2022","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.02.006","article-title":"The differential roles of HSP90 isoforms in skin inflammation: anti-inflammatory potential of TRAP1 inhibition","volume":"145","author":"Ben Abdallah","year":"2025","journal-title":"J Invest Dermatol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jamadermatol.2023.4800","article-title":"Efficacy and safety of the heat shock protein 90 inhibitor RGRN - 305 in hidradenitis suppurativa: A parallel-design double-blind trial","volume":"160","author":"Ben Abdallah","year":"2024","journal-title":"JAMA Dermatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658399\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T04:11:03Z","timestamp":1756354263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1658399\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":34,"alternative-id":["10.3389\/fimmu.2025.1658399"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1658399","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"article-number":"1658399"}}